drugset / Trial / NCT01553123

Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

NCT01553123

Phase 3 Withdrawn Watson Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether ulipristal acetate is effective in the treatment of females with anemia associated with uterine leiomyomas. The safety of this product will also be evaluated.

Timeline

Start
2012-04
Primary completion
2013-11
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulipristal Acetate Unknown Oral
Background Iron Sulfate Small molecule

Indications